{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:26:47Z","timestamp":1787030807642,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Cangrelor is the only available intravenous P2Y\n                      <jats:sub>12<\/jats:sub>\n                      inhibitor and is primarily used in patients with acute coronary syndromes (ACS), especially those presenting with cardiac arrest without prior oral P2Y\n                      <jats:sub>12<\/jats:sub>\n                      therapy. Despite guideline recommendations and evidence from the CHAMPION trials, real-world data on its use remain limited. This study evaluated real-world cangrelor use in patients with ACS, with a particular focus on transition strategies from oral P2Y\u2081\u2082 inhibitor therapy and associated treatment patterns.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cross-sectional analysis using data from a nationwide Austrian registry including 10 high-volume percutaneous coronary intervention (PCI) centers over a 7-year period. The timing of concomitant antiplatelet and anticoagulant therapy was assessed. Major adverse cardiovascular events (MACE) and bleeding complications occurring during the index hospitalization, for up to 7 days, were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 626 patients were consecutively enrolled over a 7-year period. Cangrelor was administered for a median duration of 2.5\u2005h. Marked inter-center differences were observed in transition strategies and pre-procedural antithrombotic therapy. Overall, 69% of patients received aspirin and heparin alone, whereas 31% also received an oral P2Y\n                      <jats:sub>12<\/jats:sub>\n                      inhibitor before cangrelor initiation. Among patients transitioned to a thienopyridine, 9 (6%) received clopidogrel and 6 (4%) received prasugrel before cangrelor discontinuation. Major bleeding (BARC \u22653) occurred in 46 patients (7%), without observed differences according to the timing of oral P2Y\n                      <jats:sub>12<\/jats:sub>\n                      inhibitor administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This nationwide real-world study highlights considerable variability in the clinical use of Cangrelor and its integration with oral P2Y\n                      <jats:sub>12<\/jats:sub>\n                      inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1857088","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:06Z","timestamp":1787027346000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical practice of cangrelor use in Austrian ACS patients: a real-world multicenter registry"],"prefix":"10.3389","volume":"13","author":[{"given":"Christoph","family":"Beyer","sequence":"first","affiliation":[{"name":"Department of Cardiology, Medical University Hospital Innsbruck","place":["Innsbruck, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Frick","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital of Feldkirch","place":["Feldkirch, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Toth-Gayor","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University Hospital Graz","place":["Graz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Alber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital of Klagenfurt","place":["Klagenfurt, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Siller-Matula","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Christ","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinic Favoriten, Vienna Healthcare Group","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Zenker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital of Hochsteiermark","place":["Hochsteiermark, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"Austrian Heart Foundation","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Wilfing","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Schuchlenz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital of Graz West","place":["Graz, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Plank","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University Hospital Innsbruck","place":["Innsbruck, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University Hospital Innsbruck","place":["Innsbruck, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11883-014-0401-9","article-title":"Pathophysiology of acute coronary syndrome","volume":"16","author":"Santos-Gallego","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/2048872612441582","article-title":"Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease","volume":"1","author":"Badimon","year":"2012","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1055\/s-0038-1649484","article-title":"Peri-Procedural platelet reactivity in percutaneous coronary intervention","volume":"118","author":"Alexopoulos","year":"2018","journal-title":"Thromb Haemost"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e022125","DOI":"10.1161\/jaha.121.022125","article-title":"Cangrelor: clinical data, contemporary use, and future perspectives","volume":"10","author":"De Luca","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","article-title":"Clinical use of cangrelor: nationwide experience from the Swedish coronary angiography and angioplasty registry (SCAAR)","volume":"5","author":"Grimfj\u00e4rd","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.amjcard.2017.04.034","article-title":"Safety and tolerability of transitioning from cangrelor to ticagrelor in patients who underwent percutaneous coronary intervention","volume":"120","author":"Badreldin","year":"2017","journal-title":"Am J Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"B13","year":""},{"key":"B14","doi-asserted-by":"publisher","first-page":"e024513","DOI":"10.1161\/jaha.121.024513","article-title":"Cangrelor use patterns and transition to oral P2Y(12) inhibitors among patients with myocardial infarction: initial results from the CAMEO registry","volume":"11","author":"Rymer","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jcin.2013.08.017","article-title":"Pharmacodynamic effects during the transition between cangrelor and ticagrelor","volume":"7","author":"Schneider","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1538-7836.2008.03020.x","article-title":"The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function","volume":"6","author":"Dovlatova","year":"2008","journal-title":"J Thromb Haemost"},{"key":"B19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3109\/09537104.2015.1069809","article-title":"Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro","volume":"27","author":"Judge","year":"2016","journal-title":"Platelets"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.3390\/jcm13082313","article-title":"Antiplatelet therapy and anticoagulation before, during, and after acute coronary syndrome","author":"Kaufmann","year":"2024","journal-title":"J Clin Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1857088\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:07Z","timestamp":1787027347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1857088\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":20,"alternative-id":["10.3389\/fcvm.2026.1857088"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1857088","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1857088"}}